EA200501739A1 - COMPOSITION CONTAINING PROTESTERONE RECEPTOR ANTAGONISTS AND PURE ANTIESTROGENS INTRODUCED FOR THE PREVENTION AND TREATMENT OF HORMONIZED DISEASES - Google Patents

COMPOSITION CONTAINING PROTESTERONE RECEPTOR ANTAGONISTS AND PURE ANTIESTROGENS INTRODUCED FOR THE PREVENTION AND TREATMENT OF HORMONIZED DISEASES

Info

Publication number
EA200501739A1
EA200501739A1 EA200501739A EA200501739A EA200501739A1 EA 200501739 A1 EA200501739 A1 EA 200501739A1 EA 200501739 A EA200501739 A EA 200501739A EA 200501739 A EA200501739 A EA 200501739A EA 200501739 A1 EA200501739 A1 EA 200501739A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
protesterone
hormonized
prevention
treatment
Prior art date
Application number
EA200501739A
Other languages
Russian (ru)
Other versions
EA011506B1 (en
Inventor
Ульрике Фурманн
Йенс Хоффманн
Мартин Шнайдер
Герхард Зимайстер
Original Assignee
Шеринг Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33450989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200501739(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шеринг Акциенгезельшафт filed Critical Шеринг Акциенгезельшафт
Publication of EA200501739A1 publication Critical patent/EA200501739A1/en
Publication of EA011506B1 publication Critical patent/EA011506B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны способы и применения, предназначенные для предупреждения или лечения гормонзависимых заболеваний, в частности рака молочной железы, у млекопитающего с помощью комбинации антагониста рецептора прогестерона, прежде всего антагониста рецептора прогестерона 11β-(4-ацетилфенил)-17β-гидрокси-17α-(1,1,2,2,2-пентафторэтил)эстра-4,9-диен-3-она или его фармацевтически приемлемого производного или аналога, и чистого антиэстрогена, прежде всего соединения общей формулы I, указанной в описании, например 11β-фтор-17α-метил-7α-{5-[метил(8,8,9,9,9-пентафторнонил)амино]пентил}эстра-1,3,5(10)-триен-3,17β-диола. Кроме того, изобретение относится к фармацевтическим композициям, содержащим указанную комбинацию.The application describes methods and uses for preventing or treating hormone-dependent diseases, in particular breast cancer, in a mammal using a combination of a progesterone receptor antagonist, especially an antagonist of progesterone receptor 11β- (4-acetylphenyl) -17β-hydroxy-17α- ( 1,1,2,2,2-pentafluoroethyl) estra-4,9-dien-3-one or its pharmaceutically acceptable derivative or analog, and pure antiestrogen, especially compounds of the general formula I indicated in the description, for example 11β-fluoro -17α-methyl-7α- {5- [methyl (8,8,9,9,9-penta tornonil) amino] pentyl} estra-1,3,5 (10) -triene-3,17β-diol. In addition, the invention relates to pharmaceutical compositions containing the specified combination.

EA200501739A 2003-05-28 2004-05-27 Composition comprising progesterone-receptor antagonists and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases EA011506B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/446,165 US20040242551A1 (en) 2003-05-28 2003-05-28 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
PCT/EP2004/005732 WO2004105768A1 (en) 2003-05-28 2004-05-27 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Publications (2)

Publication Number Publication Date
EA200501739A1 true EA200501739A1 (en) 2006-06-30
EA011506B1 EA011506B1 (en) 2009-04-28

Family

ID=33450989

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501739A EA011506B1 (en) 2003-05-28 2004-05-27 Composition comprising progesterone-receptor antagonists and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Country Status (18)

Country Link
US (3) US20040242551A1 (en)
EP (2) EP1628669A1 (en)
JP (1) JP2006528226A (en)
KR (1) KR20060005412A (en)
CN (1) CN1893955A (en)
AR (1) AR044450A1 (en)
AU (1) AU2004243500A1 (en)
BR (1) BRPI0410707A (en)
CA (1) CA2524750A1 (en)
CL (1) CL2004001317A1 (en)
EA (1) EA011506B1 (en)
MX (1) MXPA05012841A (en)
NO (1) NO20056153L (en)
PE (1) PE20050207A1 (en)
TW (1) TW200505936A (en)
UY (1) UY28334A1 (en)
WO (1) WO2004105768A1 (en)
ZA (1) ZA200510449B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159217A1 (en) * 2001-11-27 2003-06-05 Schering Ag 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US20070276017A1 (en) * 2003-06-10 2007-11-29 Chikara Murakata Thiadiazoline Derivative
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
CA2683809A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
TR201900954T4 (en) * 2013-04-11 2019-02-21 Bayer Pharma AG Progesterone receptor antagonist dosage form.
CN115505019B (en) * 2022-11-07 2024-01-26 南宁师范大学 7-amide substituted estrogenic compounds, and preparation method and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36654A (en) * 1970-04-24 1974-07-31 Ciba Geigy Ag 3-cyclopentyl ethers of 7alpha-methyl-3,16alpha,17(alpha and beta)-trihydroxy-delta 1,3,5(10)-estratriene,their manufacture and estrogenic pharmaceutical compositions containing them
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
DE3733478A1 (en) * 1987-10-01 1989-04-13 Schering Ag ANTIGESTAGEN AND ANTIOOTROGENIC COMPOUNDS FOR THE INTRODUCTION OF BIRTH AND PREGNANCY, AND THE TREATMENT OF GYNAECOLOGICAL DISORDER AND HORMONE-RELATED TUMORS
EP0310542B1 (en) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagenic and antioestrogenic compounds for the treatment of hormone-dependent tumours
DE19622457A1 (en) * 1996-05-24 1997-11-27 Schering Ag 7alpha- (5-methylaminopentyl) estratrienes, process for their preparation, pharmaceutical preparations which contain these 7alpha- (5-methylaminopentyl) estratrienes and their use for the manufacture of medicaments
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19635525A1 (en) * 1996-08-20 1998-02-26 Schering Ag New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives
DE19706061A1 (en) * 1997-02-07 1998-08-13 Schering Ag Anti-gestagen effective steroids with fluorinated 17alpha alkyl chain
PE20000129A1 (en) * 1997-12-23 2000-03-11 Schering Ag 11 BETA-HALOGEN-STRATRIENS SUBSTITUTED IN 7 ALPHA, AS WELL AS THE PROCEDURE TO PREPARE PHARMACEUTICAL PREPARATIONS CONTAINING SUCH 11 BETA-HALOGEN-STRATRENS SUBSTITUTED IN 7 ALPHA
DE19807791A1 (en) * 1998-02-19 1999-08-26 Schering Ag Combination preparation of estrogen with 7-aminoalkyl-estratriene antiestrogen, useful in hormone replacement therapy, e.g. for treatment osteoporosis, Alzheimer's disease and hot flushes
CZ299942B6 (en) * 2000-10-18 2008-12-29 Schering Aktiengesellschaft Pharmaceutical compositions containing antiprogestin for prevention and treatment of hormone-dependent diseases
DK1326617T3 (en) * 2000-10-18 2006-12-18 Schering Ag Use of 11beta (acetylphenyl) -17beta-hydroxy-17alpha (1,1,2,2-pentafluoroethyl) estra-4,9-dien-3-one in the manufacture of a medicament for the treatment of breast cancer, ovarian cancer, endometrial cancer , myeloma and meningitis
DE10159217A1 (en) * 2001-11-27 2003-06-05 Schering Ag 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
CN1893955A (en) 2007-01-10
US20040242551A1 (en) 2004-12-02
CL2004001317A1 (en) 2005-05-06
EA011506B1 (en) 2009-04-28
WO2004105768A8 (en) 2006-04-06
WO2004105768A1 (en) 2004-12-09
JP2006528226A (en) 2006-12-14
CA2524750A1 (en) 2004-12-09
TW200505936A (en) 2005-02-16
MXPA05012841A (en) 2006-02-13
US20050014736A1 (en) 2005-01-20
NO20056153L (en) 2006-02-22
EP1834644A3 (en) 2007-11-07
PE20050207A1 (en) 2005-04-28
AR044450A1 (en) 2005-09-14
AU2004243500A1 (en) 2004-12-09
ZA200510449B (en) 2007-04-25
US20070238714A1 (en) 2007-10-11
KR20060005412A (en) 2006-01-17
EP1834644A2 (en) 2007-09-19
BRPI0410707A (en) 2006-06-13
EP1628669A1 (en) 2006-03-01
UY28334A1 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
CY1104981T1 (en) USE OF ANTI-PROGESTONES FOR THE PREVENTION AND TREATMENT OF HORMONE DEPENDENT DISEASES
BRPI0516243C1 (en) use of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3b,17b-diol and 4-androsten-3,17-dione, use of said precursor in association with a selective estrogen receptor modulator for uterine and mammary gland protection against cancer, pharmaceutical composition and kit
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
NO20056153L (en) Preparation comprising antiprogestins and pure antiostrogens for prophylaxis and treatment of hormone-dependent diseases
JP2010539153A5 (en)
Nishino et al. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1, 4-diene-3, 17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors
EA201000097A1 (en) 8-BETA-SUBSTITUTED ESTRATRIENES AS A SELECTIVE ACTIVE STROGEN
IS7204A (en) Use of (11β, 17β) -11- (1,3-benzodioxol-5-yl) -17-hydroxy-17- (1-propynyl) -ester-4,9-din-3-one in the treatment of major depressive disorder
DK1326617T3 (en) Use of 11beta (acetylphenyl) -17beta-hydroxy-17alpha (1,1,2,2-pentafluoroethyl) estra-4,9-dien-3-one in the manufacture of a medicament for the treatment of breast cancer, ovarian cancer, endometrial cancer , myeloma and meningitis
NO20072687L (en) Pharmaceutical contraceptive preparation
JP2007510661A5 (en)
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
EA200300480A1 (en) APPLICATION OF ANTI-PROGESTINES FOR PREVENTION AND TREATMENT OF HORMONIZED DISEASES
SI20851B (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
TH76790B (en) Mixture containing progesterone-receptor antagonist and pure antistrogen For prophylaxis And hormone-dependent disease therapy

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU